Logo

Everest Medicines and Singapore's EDDC Enters into a Global Licensing Agreement to Develop and Commercialize EDDC’s 3CL Protease Inhibitors as COVID-19 Oral Antiviral Treatments Worldwide

Share this

Everest Medicines and Singapore's EDDC Enters into a Global Licensing Agreement to Develop and Commercialize EDDC’s 3CL Protease Inhibitors as COVID-19 Oral Antiviral Treatments Worldwide

Shots:

  • EDDC will receive an initial upfront payment and downstream clinical and commercial milestone payments, along with royalties on net product sales. Everest holds full rights to sub-license EDDC-2214 and will also receive full technology transfer
  • Everest will get exclusive global rights to EDDC's series of 3CL protease inhibitors that demonstrated potent in-vitro activity against SAR-CoV-2 and its variants, as well as other coronaviruses like MERS.
  • EDDC-2214 is a novel and potent SARS-CoV-2 3CL protease inhibitor which exhibits better in-vitro potency and pre-clinical oral bioavailability as compared to other oral COVID-19 antivirals. The clinical trials evaluating EDDC-2214 are anticipated to initiate later in 2022

Ref: PR Newswire | Image: PR Newswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions